These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 36822565)
1. CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer. Mavi AK; Gaur S; Gaur G; Babita ; Kumar N; Kumar U Cell Signal; 2023 May; 105():110638. PubMed ID: 36822565 [TBL] [Abstract][Full Text] [Related]
2. CAR-T cell therapy: current limitations and potential strategies. Sterner RC; Sterner RM Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268 [TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptors for the Tumour Microenvironment. Habib R; Nagrial A; Micklethwaite K; Gowrishankar K Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326 [TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208 [TBL] [Abstract][Full Text] [Related]
5. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325 [TBL] [Abstract][Full Text] [Related]
7. The role of bone marrow microenvironment on CAR-T efficacy in haematologic malignancies. Gao D; Hong F; He A Scand J Immunol; 2023 Aug; 98(2):e13273. PubMed ID: 39007933 [TBL] [Abstract][Full Text] [Related]
8. Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies. Kandav G; Chandel A Med Oncol; 2024 Oct; 41(11):275. PubMed ID: 39400611 [TBL] [Abstract][Full Text] [Related]
9. Making CAR T Cells a Solid Option for Solid Tumors. Schmidts A; Maus MV Front Immunol; 2018; 9():2593. PubMed ID: 30467505 [TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. Maus MV; Levine BL Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942 [TBL] [Abstract][Full Text] [Related]
12. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B Front Immunol; 2023; 14():1113882. PubMed ID: 37020537 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Ruella M; Korell F; Porazzi P; Maus MV Nat Rev Drug Discov; 2023 Dec; 22(12):976-995. PubMed ID: 37907724 [TBL] [Abstract][Full Text] [Related]
14. CAR-Ts: new perspectives in cancer therapy. Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080 [TBL] [Abstract][Full Text] [Related]